
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Press Release
03 May 2021
Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting
Immunicum AB (publ; IMMU.ST) announced today the publication of two abstracts for oral presentations covering preclinical data on its lead programs, ilixadencel and DCP-001, at the 18th Cancer Immunotherapy (CIMT) Annual Meeting, held virtually from Monday, May 10 to Wednesday, May 12, 2021. The accepted abstracts are now available on the conference website. The presentations cover updated preclinical data on the combination of ilixadencel with a checkpoint inhibitor targeting CTLA4 and new preclinical data on the mechanism of action of DCP-001 and its combination with the emerging immunotherapy target CD47.
“We value the opportunity to present these new encouraging data that further validate our novel immunotherapy approaches,” said Alex Karlsson-Parra, Chief Scientific Officer at Immunicum. “The data, as published today in the abstracts, supports the potential of combining immune primer ilixadencel with a checkpoint inhibitor, and underscores the important interaction with the patient’s own immune cells through the mechanism of action of DCP-001. Both presentations highlight our leadership in developing novel cell-based therapies against cancer.”
The data covered in the ilixadencel abstract published today by the conference extends data from previous preclinical experiments of ilixadencel in combination with an anti-CTLA4 checkpoint inhibitor in a CT26 colon carcinoma animal model, which demonstrated that the combination of ilixadencel and anti-CTLA4 led to complete eradication of tumors in 50-80% of the treated animals. These effects were mainly driven by CD8+ T cells and, in the new data to be presented at CIMT, characterization of CD8+ T cells from blood samples confirmed that the combination of ilixadencel and anti-CTLA4 therapy increased the frequency of CD8+ T cells with the specific markers NKG2D, CX3CR1 and CD39. These markers indicate a crucial population related to tumor-infiltrating cells with a ‘tumor-matched’ phenotype that is able to attack cancer cells.
For the abstract covering DCP-001, new preclinical data elucidate the mechanism of action through which DCP-001 can induce specific anti-tumor immunity in patients’ immune cells. The preclinical evaluation of DCP-001 mixed with the host immune cells, called peripheral blood mononuclear cells (PBMCs), shows the induction of the production of various pro-inflammatory cytokines and chemokines by these PBMCs. In addition, DCP-001 was efficiently taken up by immature monocyte-derived dendritic cells, and the blockade of the “don’t eat me” signal and emerging immunotherapy target CD47 enhanced the uptake of DCP-001. These results suggest a vital role for the patient’s immune cells in triggering the immune response upon DCP-001 vaccination and support the clinical rationale for further combination therapies including CD47 inhibitors.
Abstracts for the CIMT Annual Meeting were published today in the online program book on the CIMT conference website available via this link. eTalks will be available for registered attendees for on-demand participation at the online conference platform through June 12, 2021.
Details on the presentations are as follows:
Title: Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a “tumor-matched” phenotype
Abstract #: A-217
Session Topic: Therapeutic Vaccination
eTalk Session: eTalk Session 1, Monday, 10 May 2021; 2:00-3:00 pm (CEST)
Presenter: Alex Karlsson-Parra, Chief Scientific Officer at Immunicum
Title: CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001
Abstract #: A-337
Session Topic: Cellular Therapy
eTalk Session: eTalk Session 2, Tuesday, 11 May 2021; 5:00-6:00 pm (CEST)
Presenter: Satwinder Kaur Singh, Director of Research at Immunicum
For more information, please contact:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com
Investor Relations
Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
Media Relations
Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 175 222 57 56
E-mail: immu@trophic.eu
About Immunicum AB (publ)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin